NCT05963217 2025-07-02Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLUniversity Health Network, TorontoPhase 1 Recruiting19 enrolled
NCT02663297 2025-05-15Administration of T Lymphocytes for Prevention of Relapse of LymphomasUNC Lineberger Comprehensive Cancer CenterPhase 1 Active not recruiting18 enrolled 10 charts
NCT02658968 2024-01-16Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)Nordic NanovectorPhase 1 Completed18 enrolled 16 charts
NCT04309084 2023-02-16Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple MyelomaCelularity IncorporatedPhase 1 Unknown29 enrolled
NCT03722186 2021-03-22Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced MalignanciesJiangsu HengRui Medicine Co., Ltd.Phase 1 Suspended128 enrolled